Skip to main content

FDA Archives

Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization

Dec. 9, 2021—The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which  protects against COVID-19, discovered last year at Vanderbilt University Medical Center.

Read more


U.S. government reserves supply of COVID-19 antibody cocktail discovered at VUMC

Apr. 6, 2021—The U.S. government has reserved up to 700,000 doses of a monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca, officials have announced.

Read more


COVID treatment studied by VUMC gains FDA approval

Oct. 26, 2020—Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.

Read more


Zantac recalled for carcinogen levels above FDA standards

Nov. 27, 2019—The popular heartburn drug ranitidine, commonly known as Zantac, was voluntarily recalled due to the contamination of a human carcinogen that could potentially cause cancer. The recall includes oral tablets, capsules, and syrup.

Read more


VUMC assumes new role in FDA safety monitoring

Oct. 16, 2019—Vanderbilt University Medical Center is assuming an expanded role in U.S. Food and Drug Administration (FDA) medical product safety monitoring.

Read more


Treatment approved for patients with acute graft-versus-host disease

Jun. 13, 2019—The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC's Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.

Read more


Remote visit

Apr. 26, 2018—The chair of the U.S. Federal Communications Commission, Ajit Pai, recently visited Allen County Schools in Kentucky to see a demonstration of the new school-based telemedicine program.

Read more


Ear Community at the FDA

Mar. 22, 2018—Ron Eavey, MD, Guy M. Maness Professor and chair of Otolaryngology and director of the Vanderbilt Bill Wilkerson Center, far right, testified recently at the Food and Drug Administration in Washington, D.C., along with members of Ear Community.

Read more


Medication safety in the ICU

Sep. 19, 2017—Facilitated reporting of medication-related events in the intensive care unit can provide opportunities for optimizing quality of care and patient safety.

Read more


Investigational new drug for Alzheimer’s scheduled for first study in humans

Dec. 27, 2016—Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.

Read more


Robotic advances promise artificial legs that emulate healthy limbs

Nov. 7, 2013—Recent advances in robotics technology make it possible to create prosthetics that can duplicate the natural movement of human legs which promises to dramatically improve the mobility of lower-limb amputees.

Read more


Pneumonia vaccine for children to be tested in older adults

Oct. 11, 2012—Vanderbilt is taking part in a national study to test in older adults the use of a vaccine designed to protect children against a common cause of pneumonia.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more